Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Summary

This Phase 2a study involving Tenofovir Disoproxil Fumarate (TDF) will provide extended safety data for high-risk men. Secondarily, the study will assess the feasibility of conducting the trial and evaluate the preliminary effectiveness of TDF 300 mg as an HIV prevention method when taken once a day.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications